Furthermore, Hasan et al. demonstrated the importance of CXCR2/IL-8 signaling in tumor growth and therapy resistance to temozolomide in a patient-derived xenograft (PDX) GBM model [46]. This evidence concerns the gene CXCL8 and glioblastoma.